Glenmark Pharmaceuticals
Reco price: Rs 312
Target price: Rs 343
Glenmark reported strong sales growth of 34.5 per cent YoY, ahead of analysts and street estimates driven by US, EU and RoW formulation segments. The disappointment came in from the high-margin domestic segment, which grew by mere 11.3 per cent YoY, impacted by inventory rationalisation. The company also incurred higher R&D cost during the quarter. In spite of strong rupee depreciation, Glenmark reported recurring operating margin of 18.0 per cent, well below estimates. Pinc Research has cut its FY13 earning estimates by three per cent to factor in higher R&D expenses which are offset by lower tax rate. Downgrade to Accumulate.

Pinc Research